AGRX - Agile Therapeutics (NASDAQ: AGRX) Upgraded To Buy Rating By Analysts At Maxim Group | Benzinga

Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research. The firm’s focus and area of expertise is in small and micro-cap companies, some of which are poised for growth. In a recent report, the research team at Maxim Group outlined why it has upgraded Agile Therapuetics Inc. (NASDAQ: AGRX) to a "buy” rating.

Agile Therapeutics is a women’s healthcare company that is "dedicated to fulfilling the unmet needs of today’s women.” Its product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options. The company’s lead product, Twirla®, is a weekly birth control patch. Twirla delivers its medicine through skin contact, eliminating the need for a daily pill. 

Maxim Group has changed its recommendation for the stock to buy, explaining that "fundamental metrics and/or ...

AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group>Full story available on Benzinga.com